ArticleThe American journal of pathology2001
CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.
Article in The American journal of pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.Molecular diagnosis & therapy · 2019Pooled it
- Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies.BioMed research international · 2014Pooled it
- CLINICAL utility of assessing CDKN2A status in recurrent astrocytomas.Brain tumor pathology · 2025Article
- Article
- Genetic study of thePractical laboratory medicine · 2024Article
- Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy.CEN case reports · 2017Article
- Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer.Oncotarget · 2016Article
- Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms.BioMed research international · 2015Review
- Downregulation of NDUFB6 due to 9p24.1-p13.3 loss is implicated in metastatic clear cell renal cell carcinoma.Cancer medicine · 2015Article
- Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.British journal of cancer · 2014Article
- Biomarkers in renal cancer.Virchows Archiv : an international journal of pathology · 2014Review
- The VHL/HIF axis in clear cell renal carcinoma.Seminars in cancer biology · 2013Review
- Significance of CDKN2A gene A148T variant in patients with bladder cancer.Central European journal of urology · 2011Article
- Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.International journal of cancer · 2009Article
- Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.Cancer research · 2009Article
- Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.Neoplasia (New York, N.Y.) · 2008Article
- [Exploration of tumor suppressors p16INK4a and p14ARF in oral leukoplakias].Mund-, Kiefer- und Gesichtschirurgie : MKG · 2007Article
- Article
- Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.The American journal of pathology · 2003Article
- Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.British journal of cancer · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inactivation of tumor suppressor genes on chromosome 9p is considered a critical event in renal cell carcinoma pathogenesis. Alterations of CDKN2A on 9p21 have been reported in renal cancer cell lines, but their relevance for primary renal carcinomas is unclear. Loss of heterozygosity (LOH) was analyzed by using four polymorphic microsatellites at D9S970 (9p12-9p13), D9S171 (9p13), D9S1748 (9p21), and D9S156 (9p21) in 113 primary conventional clear-cell renal cell carcinomas (CRCCs). Allelic deletion was detected in 21 of 88 informative CRCCs (24%) with the highest rate of LOH being observed at D9S171 on 9p13 (20%). Chromosome 9p LOH was associated with short tumor-specific survival in stage pT3 RCC (P = 0.01). Fluorescence in situ hybridization analysis of 54 CRCCs revealed no homozygous CDKN2A deletions indicating that this mechanism of CDKN2A inactivation is rare in CRCC. Sequencing of 113 CRCCs showed that 13 tumors (12%) had a 24-bp deletion abrogating codons 4 through 11 of CDKN2A. Immunohistochemical CDKN2A expression was absent in normal renal tissue and was only detected in six of 382 CRCCs (1.5%) on a renal tumor microarray. These data suggest that CDKN2A alterations are present in a small subset of CRCCs and a second, yet unknown tumor suppressor gene proximal to the CDKN2A locus, may play a role in CRCC development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.